Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
adult patients, \>=18 years of age;
non-small cell lung cancer, stage IIIb (with effusion) or stage IV with measurable disease ;
ECOG PS 2;
adequate organ function.
You may not be if
prior chemotherapy or systemic anti-tumor therapy;
hypersensitivity to erlotinib;
any condition contraindicating the use of the study medication and/or impairing the interpretation of results and/or leading to treatment-related complications.
Clareo Health | A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
